Oncolines cancer cell panel profiling

The activity of compound is determined in viability assays on a large panel of well-characterized human cancer cell lines. More than 250 cell lines are available for profiling study, while the standard panel comprises of 102 tumour cell lines. The cell viability assay data are subjected to bioinformatic analyses to identify drug response biomarkers and to determine tissue selectivity. The predictive drug response biomarkers can be used in the experimental design of subsequent in vivo or ex vivo validation experiments. Once validated, these biomarkers can form the basis for selecting the patient population most likely to respond to your compound in proof-of-concept clinical trials.